New allergy vaccine shows promise in early safety trial
NCT ID NCT07317960
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This early-stage study tests a new vaccine called PollenVax for people with moderate to severe mugwort pollen allergy. The main goal is to see if the vaccine is safe and tolerable in 30 adults aged 18 to 65. Participants receive four shots of either the vaccine or a placebo, and researchers monitor for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC RHINITIS DUE TO ARTEMISIA POLLEN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Limited Liability Partnership "Medcenter-Rakhat"
Almaty, Almaty, 050000, Kazakhstan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Antiviral drug ganciclovir explored as new weapon against stubborn allergies
- New allergy shot aims to tame mugwort season in just four weeks
- New nasal spray shows promise for ragweed allergy sufferers
- SNIFF TEST: nasal swab may reveal lung disease severity
- New study checks allergy Pill's safety and symptom relief
- New allergy shots show promise for dust mite sufferers